Tags

Type your tag names separated by a space and hit enter

Genetic abnormalities in pancreatic cancer.

Abstract

The incidence and mortality of pancreatic adenocarcinoma are nearly coincident having a five-year survival of less than 5%. Enormous advances have been made in our knowledge of the molecular alterations commonly present in ductal cancer and other pancreatic malignancies. One significant outcome of these studies is the recognition that common ductal cancers have a distinct molecular fingerprint compared to other nonductal or endocrine tumors. Ductal carcinomas typically show alteration of K-ras, p53, p16INK4, DPC4 and FHIT, while other pancreatic tumor types show different aberrations. Among those tumors arising from the exocrine pancreas, only ampullary cancers have a molecular fingerprint that may involve some of the same genes most frequently altered in common ductal cancers. Significant molecular heterogeneity also exists among pancreatic endocrine tumors. Nonfunctioning pancreatic endocrine tumors have frequent mutations in MEN-1 and may be further subdivided into two clinically relevant subgroups based on the amount of chromosomal alterations. The present review will provide a brief overview of the genetic alterations that have been identified in the various subgroups of pancreatic tumors. These results have important implications for the development of genetic screening tests, early diagnosis, and prognostic genetic markers.

Links

  • PMC Free PDF
  • PMC Free Full Text
  • Authors+Show Affiliations

    ,

    Dipartimento di Patologia, Università di Verona, Strada Le Grazie, 37134, Verona, Italy. p.moore@univr.it

    , ,

    Source

    Molecular cancer 2: 2003 Jan 07 pg 7

    MeSH

    Acid Anhydride Hydrolases
    Biomarkers, Tumor
    Cyclin-Dependent Kinase Inhibitor p16
    DNA-Binding Proteins
    Genes, ras
    Humans
    Mutation
    Neoplasm Proteins
    Pancreatic Neoplasms
    Smad4 Protein
    Trans-Activators
    Tumor Suppressor Protein p53

    Pub Type(s)

    Journal Article
    Research Support, Non-U.S. Gov't
    Review

    Language

    eng

    PubMed ID

    12537585

    Citation

    Moore, Patrick S., et al. "Genetic Abnormalities in Pancreatic Cancer." Molecular Cancer, vol. 2, 2003, p. 7.
    Moore PS, Beghelli S, Zamboni G, et al. Genetic abnormalities in pancreatic cancer. Mol Cancer. 2003;2:7.
    Moore, P. S., Beghelli, S., Zamboni, G., & Scarpa, A. (2003). Genetic abnormalities in pancreatic cancer. Molecular Cancer, 2, p. 7.
    Moore PS, et al. Genetic Abnormalities in Pancreatic Cancer. Mol Cancer. 2003 Jan 7;2:7. PubMed PMID: 12537585.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Genetic abnormalities in pancreatic cancer. AU - Moore,Patrick S, AU - Beghelli,Stefania, AU - Zamboni,Giuseppe, AU - Scarpa,Aldo, Y1 - 2003/01/07/ PY - 2002/12/06/received PY - 2003/01/07/accepted PY - 2003/1/23/pubmed PY - 2004/11/16/medline PY - 2003/1/23/entrez SP - 7 EP - 7 JF - Molecular cancer JO - Mol. Cancer VL - 2 N2 - The incidence and mortality of pancreatic adenocarcinoma are nearly coincident having a five-year survival of less than 5%. Enormous advances have been made in our knowledge of the molecular alterations commonly present in ductal cancer and other pancreatic malignancies. One significant outcome of these studies is the recognition that common ductal cancers have a distinct molecular fingerprint compared to other nonductal or endocrine tumors. Ductal carcinomas typically show alteration of K-ras, p53, p16INK4, DPC4 and FHIT, while other pancreatic tumor types show different aberrations. Among those tumors arising from the exocrine pancreas, only ampullary cancers have a molecular fingerprint that may involve some of the same genes most frequently altered in common ductal cancers. Significant molecular heterogeneity also exists among pancreatic endocrine tumors. Nonfunctioning pancreatic endocrine tumors have frequent mutations in MEN-1 and may be further subdivided into two clinically relevant subgroups based on the amount of chromosomal alterations. The present review will provide a brief overview of the genetic alterations that have been identified in the various subgroups of pancreatic tumors. These results have important implications for the development of genetic screening tests, early diagnosis, and prognostic genetic markers. SN - 1476-4598 UR - https://www.unboundmedicine.com/medline/citation/12537585/Genetic_abnormalities_in_pancreatic_cancer_ L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/12537585/ DB - PRIME DP - Unbound Medicine ER -